Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634606 · ClinicalTrials.gov registry record · Phase 3
Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood
A Phase 3 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT02634606: Clinical Trial Phase 3 study, sponsored by University of California, Los Angeles.
NCT02634606 is a Phase 3 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 13 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02634606, a Phase 3 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
Elevated blood cholesterol, and particularly LDL cholesterol, is a risk factor for heart disease. Tocotrienols are naturally-occurring compounds in foods that may have beneficial effects on blood cholesterol. Tocotrienols are members of the vitamin E family, and are found in barley, oats, rye, coconut oil and rice bran oil, but the richest source of tocotrienols is palm oil. Certain of these tocotrienols have been shown to be effective in lowering LDL (or 'bad') cholesterol, with no adverse effects on the HDL (or 'good') cholesterol. The purpose of this study is to determine the effects of a palm-oil derived tocotrienol supplement on blood cholesterol, and particularly LDL cholesterol, in individuals who are taking statins, and have either elevated or normal cholesterol levels. Study subjects will consume a palm-oil derived supplement of tocotrienol for 3 months to determine its effects on LDL cholesterol.
Primary Outcome
Mixed-effects regression models will be used to evaluate the change in LDL cholesterol over time between the 3 groups
Interventions
- DRUG Sugar Pill
- DRUG Gamma Delta Tocotrienols - Low Dose
- DRUG Gamma Delta Tocotrienols - High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2015-11-13 |
| Phase | Phase 3 |
Why NCT02634606 stopped before completion
NCT02634606 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Sugar Pill is the first listed.
NCT02634606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02634606 about?
NCT02634606 is a clinical study titled "Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood". Elevated blood cholesterol, and particularly LDL cholesterol, is a risk factor for heart disease. Tocotrienols are naturally-occurring compounds in foods that may have beneficial effects on blood cholesterol. Tocotrienols are members of the vitamin E family, and are found in barley, oats, rye, cocon...
What is the current status of trial NCT02634606?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2011-03-22. Estimated completion is 2015-11-13.
What interventions are being tested in trial NCT02634606?
The interventions under investigation include: Sugar Pill (DRUG), Gamma Delta Tocotrienols - Low Dose (DRUG), Gamma Delta Tocotrienols - High Dose (DRUG).
Who is sponsoring clinical trial NCT02634606?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02634606's enrollment target sits among peer trials
13 1984th of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI